Anti-Human Metapneumovirus, Matrix Protein (HMPV-2160)
Anti-Human Metapneumovirus, Matrix Protein (HMPV-2160)
Product No.: M224
- -
- -
Clone HMPV-2160 Target Matrix Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names HMPV Isotype Mouse IgG2a Applications ELISA , IF , Lateral Flow |
- -
- -
Antibody DetailsProduct DetailsReactivity Species Human metapneumovirus Host Species Mouse Product Concentration ≥1.0 mg/ml Purity ≥90% Formulation Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations. Storage and Handling This purified antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco ELISA: 1:20-1:200, IF: 1:10-1:50 Additional Applications Reported In Literature ? Lateral Flow Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Anti-HMPV (Clone HMPV-2160) is specific for the matrix protein of human Metapneumovirus genotypes A & B. It is not cross-reactive with RSV, Influenza A, Influenza B, Adenovirus, or Parainfluenza viruses 1, 2, & 3. Matched Pair Best Lateral Flow pair (capture/detection), HMPV-2713/HMPV-2160 Background Human Metapneumovirus (HMPV) is a single-stranded RNA virus belonging to the Paramyxoviridae family and is considered one of the major respiratory pathogens responsible for acute respiratory tract infections in humans. HMPV was first identified in 2001 and has since been recognized globally as a common cause of respiratory illnesses, particularly in young children, the elderly, and immunocompromised individuals. The virus spreads through respiratory droplets and can cause a wide spectrum of clinical manifestations, ranging from mild cold-like symptoms to severe lower respiratory tract infections, including bronchiolitis and pneumonia. HMPV shares similarities with Respiratory Syncytial Virus (RSV) and Influenza Virus in terms of its clinical presentation and seasonality, often peaking in the winter months in temperate regions. While most infections are self-limiting, severe cases can lead to hospitalization, making HMPV an important consideration in the differential diagnosis of respiratory infections, especially in vulnerable populations. Currently, there is no specific antiviral treatment for HMPV infections, emphasizing the importance of supportive care and preventive measures to reduce its impact on public health. Antigen DetailsResearch Area Infectious Disease . Matched Pair . Seasonal and Respiratory Infections . Viral . IVD Raw Material References & Citations1. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD) Technical Protocols IF Lateral Flow |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
